Professor of Medicine, Director, Hepatobiliary Disease Interest Group, Div. of Gastroenterology & Hepatology
Mayo Clinic
Manal F. Abdelmalek, MD, MPH, FAASLD is a Professor of Medicine, Director of the Hepatobiliary Interest Group and Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota.
Her clinical and research interest has focused on NAFLD/NASH, associated risk factors for disease acquisition and progression and discovery of novel approaches to treatment. She has expertise in clinical-translational research, design and conduct of clinical trials, industry sponsored and NIH-funded studies evaluating new therapies and biomarkers for NAFLD/NASH. She collaborates extensively to transition new compounds to first-in-man clinical studies, translates clinic-to-bench/bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/consultant to many industries, FDA, and biomarker development companies in diagnostics and therapeutics for NASH.
She is the PI on several multicenter global studies, a member of the AASLD Global Outreach and Engagement Committee and past member of the AASLD Clinical Research Committee. As a teacher and educator, she has mentored clinical residents, fellows, and faculty in the study and research of liver disease. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a steering committee member of the NIH Liver Cirrhosis Network and a former 16-year member NASH Clinical Research Network . Dr. Abdelmalek has published more than 200 manuscripts and is an Associate Editor of HEPATOLOGY, the official journal of the AASLD.
Tuesday, September 12, 2023
1:30 PM - 3:00 PM PT
Disclosure(s): 89 Bio: Consultant/Advisory Board (); Celgene/ Bristol-Myers Squibb: Consultant/Advisory Board (); Clinical Care Options: Consultant/Advisory Board (); Fishawack, Inc: Consultant/Advisory Board (); Hanmi: Consultant/Advisory Board (); Intercept: Consultant/Advisory Board (); Inventiva: Consultant/Advisory Board (); Madrigal: Consultant/Advisory Board (); Medscape: Consultant/Advisory Board (); Merck: Consultant/Advisory Board (); NGM Bio: Consultant/Advisory Board (); Novo Nordisk: Consultant/Advisory Board (); SonicIncytes: Consultant/Advisory Board (); Terra Firma, Inc.: Consultant/Advisory Board (); Theratechnologies: Consultant/Advisory Board ()
2 - Pathophysiologic Changes, Staging, Diagnosis & Trial Endpoints for NAFLD/NASH
Tuesday, September 12, 2023
1:30 PM - 3:00 PM PT
Disclosure(s): 89 Bio: Consultant/Advisory Board (); Celgene/ Bristol-Myers Squibb: Consultant/Advisory Board (); Clinical Care Options: Consultant/Advisory Board (); Fishawack, Inc: Consultant/Advisory Board (); Hanmi: Consultant/Advisory Board (); Intercept: Consultant/Advisory Board (); Inventiva: Consultant/Advisory Board (); Madrigal: Consultant/Advisory Board (); Medscape: Consultant/Advisory Board (); Merck: Consultant/Advisory Board (); NGM Bio: Consultant/Advisory Board (); Novo Nordisk: Consultant/Advisory Board (); SonicIncytes: Consultant/Advisory Board (); Terra Firma, Inc.: Consultant/Advisory Board (); Theratechnologies: Consultant/Advisory Board ()